TABLE 4.
Risk factors for hospital admission after infection. Univariable and multivariable Cox regression with monoclonal antibody treatment as a time-updated variable
| Unadjusted model |
Adjusted modela |
|||||
|---|---|---|---|---|---|---|
| HR | 95% CI | p-value | HR | 95% CI | p-value | |
| Age per 10 years | 7.50 | 0.82–68.34 | 0.074 | 6.05 | 0.71–51.28 | 0.099 |
| Male sex | 1.47 | 0.77–2.82 | 0.136 | — | — | — |
| Transplantation type (liver Tx as reference) | 1.85 | 0.87–3.95 | 0.110 | 1.93 | 0.52–0.89 | 0.096 |
| Transplanted within the last year from the start of follow-up or after follow-up | 1.34 | 0.53–3.40 | 0.542 | — | — | — |
| Number of vaccines before the infection (0 and 1 as reference) | ||||||
| 2 | 0.64 | 0.33–1.24 | 0.185 | 0.70 | 0.35–1.38 | 0.299 |
| 3 | 0.312 | 0.15–0.67 | 0.003 | 0.42 | 0.19–0.89 | 0.025 |
| Immunosuppressive treatment | ||||||
| Antimetabolite at time of infection (none as reference) | ||||||
| Mycophenolate | 0.81 | 0.33–1.97 | 0.648 | — | — | — |
| Azathioprine | 0.59 | 0.11–3.30 | 0.550 | — | — | — |
| Corticosteroids at time of infection | 1.49 | 0.60–3.71 | 0.386 | — | — | — |
| CNI or mTOR at time of infection (CNI as reference) | ||||||
| mTOR | 2.82 | 0.74–10.77 | 0.128 | — | — | — |
| None | 1.47 | 0.34–6.31 | 0.607 | — | — | — |
| Outpatient monoclonal antibody treatment | 0.11 | 0.01–0.76 | 0.026 | 0.15 | 0.02–1.05 | 0.057 |
| Comorbidities | ||||||
| Cardiovascular disease | 1.51 | 0.79–2.90 | 0.219 | — | — | — |
| Chronic pulmonary disease | 1.15 | 0.50–2.66 | 0.746 | — | — | — |
| Diabetes mellitus | 1.50 | 0.80–2.84 | 0.209 | — | — | — |
Abbreviations: CI, confidence interval; CNI, calcineurin inhibitor; HR, hazard ratio; mTOR, mamalian target of rapamycin.
a
The adjusted model is adjusted for age, transplantation type, number of vaccination, and outpatient monoclonal antibody treatment.